P4‐708: CLINICAL BIOMARKER EVIDENCE FOR TARGET ENGAGEMENT, REDUCTION OF SYNAPTIC DAMAGE AND DISEASE MODIFICATION IN ALZHEIMER'S PATIENTS TREATED WITH CT1812. (1st July 2019)